If the vaccine is given the go-ahead to enter into human clinical trials, it will be at least four years before Kang expects to have statistically significant analysis, and possibly allow the vaccine to be marketed.
Through Western, Sumagen Canada has secured patents for the vaccine in over 70 countries in the world, including the United States, the European Union and Korea. According to the firm, animal testing has resulted in good antibody reactions in immunology tests, with no adverse effects or safety risks.
Sumagen says it is prepared to begin the clinical trial in the U.S. as soon as approval is granted.
HIV/AIDS vaccine reaches milestone
By Communications Staff
Thursday, July 2, 2009
An HIV/AIDS vaccine developed by University of Western Ontario professor Chil-Yong Kang has reached "an important milestone" as it pushes towards the first phase of human trials.
